Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Miho, Kamezawa"'
Autor:
Yoshihisa Toda, Shinsuke Kaku, Shogo Kawabata, Miho Kamezawa, Masanori Sugimoto, Ichimaro Yamada, Noboru Otsuka, Hideo Matsumoto, Hiromi Endo
Publikováno v:
Pharmacology & Pharmacy. :305-312
We developed a novel topical non-steroidal anti-inflammatory drug (NSAID)patch, S(+)-flurbiprofen plaster, (SFPP), containing S(+)-flurbiprofen (SFP), an enantiomer of flurbiprofen (FP). In a previous study conducted in an animal model, we showed goo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::821c733207e5f0bb019a03372d06440b
https://doi.org/10.4236/pp.2016.78037
https://doi.org/10.4236/pp.2016.78037
Autor:
Yuichi Hoshino, Noboru Otsuka, Ichimaro Yamada, Isao Matsushita, Hideo Matsumoto, Kazuo Uebaba, Miho Kamezawa, Ikuko Yataba, Sigeru Sasaki
Publikováno v:
European Journal of Clinical Pharmacology
Purpose The purpose of this study is to investigate the pharmacokinetics and deep tissue penetration capability of the newly developed S-flurbiprofen plaster (SFPP) in humans. Methods Study 1: SFPP tape-type patch (2–60 mg) was applied to the lower
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93baed6e8f469971817aa8ff23de642c
http://europepmc.org/articles/PMC4701782
http://europepmc.org/articles/PMC4701782
Autor:
Ichimaro Yamada, Kazuo Uebaba, Miho Kamezawa, Noboru Otsuka, Yuichi Hoshino, Isao Matsushita, Hideo Matsumoto, Shigeru Sasaki, Ikuko Yataba
Publikováno v:
European Journal of Clinical Pharmacology. 72:511-511
Erratum to: Eur J Clin Pharmacol (2016) 72:53–59 DOI 10.1007/s00228-015-1960-6 One of the authors name, Shigeru Sasaki, was erroneously spelled in the original paper. The authors apologize for the inconvenience caused.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::41d3a9c8925897c7b20382ce824317d3
https://doi.org/10.1007/s00228-016-2007-3
https://doi.org/10.1007/s00228-016-2007-3
Autor:
Atsushi Fukunari, Takanori Oe, Yoichi Naka, Seigo Ishibuchi, Tsuguo Ikebe, Hiroshi Morimoto, Ichimaro Yamada, Miho Kamezawa, Hiroyoshi Inoue
Publikováno v:
ChemInform. 32
A series of 1-phenylpyrazoles was evaluated for inhibitory activity against xanthine oxidase in vitro. Of the compounds prepared, 1-(3-cyano-4-neopentyloxyphenyl)pyrazole-4-carboxylic acid (Y-700) had the most potent enzyme inhibition and displayed l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::78fdbfd650314b9307c626149025262b
https://doi.org/10.1002/chin.200150107
https://doi.org/10.1002/chin.200150107
Autor:
Emil F. Pai, Atsushi Fukunari, Ichimaro Yamada, Takeshi Nishino, Ken Okamoto, Norihisa Kato, Bryan T. Eger, Miho Kamezawa
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 311(2)
Y-700 (1-[3-Cyano-4-(2,2-dimethylpropoxy)phenyl]-1H-pyrazole-4-carboxylic acid) is a newly synthesized inhibitor of xanthine oxidoreductase (XOR). Steady-state kinetics with the bovine milk enzyme indicated a mixed type inhibition with K(i) and K(i)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ec190249fc344bca01725b4a34f0c5f
https://pubmed.ncbi.nlm.nih.gov/15190124
https://pubmed.ncbi.nlm.nih.gov/15190124
Autor:
Hiroshi Morimoto, Tsuguo Ikebe, Atsushi Fukunari, Yoichi Naka, Takanori Oe, Ichimaro Yamada, Seigo Ishibuchi, Hiroyoshi Inoue, Miho Kamezawa
Publikováno v:
Bioorganicmedicinal chemistry letters. 11(7)
A series of 1-phenylpyrazoles was evaluated for inhibitory activity against xanthine oxidase in vitro. Of the compounds prepared, 1-(3-cyano-4-neopentyloxyphenyl)pyrazole-4-carboxylic acid (Y-700) had the most potent enzyme inhibition and displayed l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7106faab40971656ad68c7636cf3101a
https://pubmed.ncbi.nlm.nih.gov/11294382
https://pubmed.ncbi.nlm.nih.gov/11294382
Autor:
Atsushi, Fukunari, Ken, Okamoto, Takeshi, Nishino, T, Eger Bryan, F, Pai Emil, Miho, Kamezawa, Ichimaro, Yamada, Norihisa, Kato
Publikováno v:
The Journal of Pharmacology and Experimental Therapeutics; November 2004, Vol. 311 Issue: 2 p519-28, 10p